Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
NCT06085456 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2023-10-17
Summary
The purpose of this study is to identify the demographic and sociological characteristics of epithelial ovarian cancer in a cohort, identify the risk factors of epithelial ovarian cancer, effectively identify the high-risk population of epithelial ovarian cancer in the population, implement standardized health management, and clarify the effect of standardized health management on the incidence and prognosis of epithelial ovarian cancer. It can also provide a case control population for the clinical cohort of epithelial ovarian cancer to benefit the majority of postoperative patients.
Conditions
- Epithelial Ovarian Cancer
Interventions
- DIAGNOSTIC_TEST
-
Hematologic features
Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
Sponsors & Collaborators
-
RenJi Hospital
lead OTHER
Principal Investigators
-
Aimin Zhao, MD · RenJi Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-09-01
- Primary Completion
- 2024-06-30
- Completion
- 2024-06-30
Countries
- China
Study Locations
More Related Trials
-
Survival Outcomes of Ovarian Malignancies in Chinese Population
NCT03291262 ·Status: UNKNOWN
-
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
NCT05574673 ·Status: RECRUITING
-
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923 ·Status: RECRUITING
-
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer
NCT05446545 ·Status: RECRUITING
-
To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
NCT06315270 ·Status: NOT_YET_RECRUITING
-
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
NCT04582552 ·Status: UNKNOWN
-
The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study
NCT05265117 ·Status: UNKNOWN
-
Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
NCT05371301 ·Status: UNKNOWN ·Phase: PHASE3
-
Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
NCT06366997 ·Status: COMPLETED
-
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122 ·Status: COMPLETED
-
Lymphadenectomy in Early Ovarian Cancer
NCT04710797 ·Status: RECRUITING ·Phase: NA
-
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
NCT01611766 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase III Trial of Stage I Ovarian Cancer After Surgery
NCT04063527 ·Status: RECRUITING ·Phase: PHASE3
-
A Cohort Establishment Study of Total Management of Ovarian Cancer
NCT06018935 ·Status: RECRUITING
-
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091 ·Status: UNKNOWN
-
Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer
NCT00003794 ·Status: TERMINATED
-
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320 ·Status: UNKNOWN
-
Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT03858166 ·Status: TERMINATED ·Phase: PHASE4
-
Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer
NCT06574763 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Homologous Recombination Inquiry Through Ovarian Malignancy Investigations
NCT03159572 ·Status: COMPLETED
-
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
NCT06775470 ·Status: RECRUITING
-
Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
NCT06883487 ·Status: RECRUITING
-
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
NCT02900560 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom
NCT00757263 ·Status: UNKNOWN
-
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
NCT05633199 ·Status: NOT_YET_RECRUITING ·Phase: NA